Startup profile for Counsel Health: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Counsel Health funding, valuation and investors

Physician-supervised async AI medical advice via messaging for employers and health plans.

Keep track of Counsel Health

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$25M · 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$36M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · New York, New York

Investors in latest funding

Lead: Andreessen Horowitz

Other: Kleiner Perkins

Sources: latest funding Last verified: 2026-07-25

Overview

Counsel Health combines AI-generated health guidance with licensed physician oversight — delivering async medical advice via secure messaging for employers and health plans. The hybrid model aims to scale primary-care access without replacing clinicians. Counsel raised an $11M seed in 2024 led by a16z Bio+Health with Asymmetric Capital, Floodgate, and Pear VC, then a $25M Series A in 2025 co-led by a16z and GV with Kleiner Perkins participating.

Why Counsel Health is interesting

Hybrid AI-clinician model for messaging-based care — Pear and Floodgate in seed; Kleiner joined a16z in the $25M Series A as employers seek scalable virtual primary care.

Product & use cases

Counsel delivers async medical messaging where AI drafts responses reviewed by licensed physicians — giving employees 24/7 access without synchronous telehealth waits.

  • Employer-sponsored virtual primary care and triage
  • Health-plan supplemental access for underserved members
  • Chronic condition check-ins between in-person visits

Key facts

  • Series A (2025): $25M co-led by a16z and GV; Kleiner Perkins participated (BusinessWire)
  • Seed (2024): $11M led by a16z Bio+Health; Pear, Floodgate, Asymmetric (PR Newswire)

Funding history (newest first)

Investors in our directory

Funds linked from Counsel Health's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Physician-in-the-loop async model — AI handles volume while clinicians maintain medical liability and quality standards.

Virtual care platforms compete on employer contracts, clinical quality, and unit economics. Counsel's async AI+physician model targets lower cost per encounter than video visits. Regulatory scrutiny on AI medical advice makes physician oversight a differentiator.

  • 98point6 direct

    Text-based primary care; Counsel adds explicit AI+physician hybrid.

  • Teladoc incumbent

    Broad telehealth incumbent; async messaging is one product line.

  • K Health direct

    AI-first symptom checker with clinician chat; similar consumer/employer overlap.

  • Hims & Hers adjacent

    DTC telehealth; narrower condition focus than primary care.

Notable stories

  • Counsel's founders built the company on the thesis that most primary-care questions don't need a 15-minute video visit — async AI+physician messaging can scale access (a16z Bio+Health, 2024).

Industries

Healthtech AI & Machine Learning

Related funding articles

Venture Capital Tracker pieces that cover Counsel Health's financing or category context.

FAQs about Counsel Health

Practical answers founders, operators, and investors typically search for.

Async medical advice via messaging — AI drafts responses reviewed by licensed physicians for employers and health plans.
a16z (/fund/andreessen-horowitz) led seed and co-led Series A. Kleiner (/fund/kleiner-perkins), Pear (/fund/pear-vc), and Floodgate (/fund/floodgate) participated.
No — licensed physicians supervise all medical advice; AI handles drafting and triage.
Teladoc offers broad telehealth including video; Counsel focuses on async AI+physician messaging.
Seed in 2024 ($11M), Series A in 2025 ($25M).
Operates under physician practice and telehealth regulations — not a standalone medical device.
Employers and health plans seeking virtual primary care access.
Not publicly disclosed.
New York.
No.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.